Twist Bioscience (TWST) EBT Margin (2017 - 2026)

Twist Bioscience (TWST) has reported EBT Margin for 10 consecutive years, with 29.35% the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT Margin fell 5077.0% year-over-year to 29.35% in Q2 2026; TTM through Jun 2026 was 31.46%, a 805.0% decrease from a year earlier, with the FY2025 full-year figure at 20.43%, up 4608.0% from the prior year.
• EBT Margin was 29.35% for Q2 2026 at Twist Bioscience, up from 39.72% in the prior quarter.
• Over five years, EBT Margin peaked at 21.43% in Q2 2025 and troughed at 126.37% in Q1 2022.
• A 5-year average of 61.29% and a median of 59.97% in 2023 frame the typical range for EBT Margin.
• Across the five-year window, EBT Margin soared 12623 bps in 2025 and plunged 5077 bps in 2026, its largest moves.
• Over 5 years, EBT Margin stood at 76.96% in 2022, then gained by 22 bps to 59.98% in 2023, then surged by 41 bps to 35.5% in 2024, then increased by 18 bps to 29.18% in 2025, then decreased by 1 bps to 29.35% in 2026.
• The last three EBT Margin figures came in at 29.35% (Q2 2026), 39.72% (Q1 2026), and 29.18% (Q4 2025), per Business Quant data.